Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels
Year: 2013
Type: article
Abstract: Cancer and stromal cells actively exert physical forces (solid stress) to compress tumour blood vessels, thus reducing vascular perfusion. Tumour interstitial matrix also contributes to solid stress, with hyaluronan implicated as the primary matrix molecule responsible for vessel compression because of its swelling behaviour. Here we show, unexpectedly, that hyaluronan compresses vessels only in collagen-rich tumours, suggesting that collagen and hyaluronan together are critical targets for decompressing tumour vessels. We demonstrate that the angiotensin inhibitor losartan reduces stromal collagen and hyaluronan production, associated with decreased expression of profibrotic signals TGF-β1, CCN2 and ET-1, downstream of angiotensin-II-receptor-1 inhibition. Consequently, losartan reduces solid stress in tumours resulting in increased vascular perfusion. Through this physical mechanism, losartan improves drug and oxygen delivery to tumours, thereby potentiating chemotherapy and reducing hypoxia in breast and pancreatic cancer models. Thus, angiotensin inhibitors —inexpensive drugs with decades of safe use — could be rapidly repurposed as cancer therapeutics. Hyaluronan is a component of the tumour extracellular matrix. Here, Chauhan et al. show that hyaluronan increases blood pressure in collagen-rich tumours by compressing vessel walls, and that reducing the level of hyaluranon with an angiotensin II inhibitor increases blood flow and drug penetrance in tumours.
Source: Nature Communications
DOI: 10.1038/ncomms3516
Authors: Vikash P. Chauhan, John D. Martin, Hao Liu, Delphine A. Lacorre, Saloni R. Jain, Sergey V. Kozin, Triantafyllos Stylianopoulos, Ahmed S. Mousa, Xiaoxing Han, Pichet Adstamongkonkul, Zoran Popović, Peigen Huang, Moungi G. Bawendi, Yves Boucher, Rakesh K. Jain
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $6,990
Funders: U.S. Department of Defense, Lustgarten Foundation, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, National Institutes of Health, National Cancer Institute, National Institute of Biomedical Imaging and Bioengineering, National Center for Research Resources
Awards: Role of BMDCs in Solid Tumor Growth and Relapse, STRATEGIES FOR PERSONALIZED TREATMENT OF METASTATIC BREAST CANCER: VASCULAR NORMALIZATION AND SENSITIZATION, Training Program in Integrative Pathophysiology of Solid Tumors, Integrative Biology of Tumor Metastasis, G3727540050, G4119534169, G4998455160, Doppler Optical Frequency Domain Imaging Instrument, Integrative Pathophysiology of Solid Tumors, Probing Tumor Microenvironment Using Nanotechnology, G5850682332, Transport of Large Molecules and Viral Vectors in Tumors: Effects of Cytotoxic an, G9000317666, Center for Biomedical OCT Research and Translation
OpenAlex ID: W1603491949
